Effects of XOMA 052 on Insulin Production in Type 1 Diabetes

Phase 2 Completed 22 enrolled University of Zurich XOMA (US) LLC · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

To assess the effects of treatment with XOMA 052 on beta-cell function and insulin production in subjects with well-controlled Type 1 diabetes. The safety, tolerability, and pharmacokinetics (PK) of XOMA 052 will also be assessed.

Timeline

Start: 2009-09
Primary completion: 2013-09
Completion: 2013-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	gevokizumab	Monoclonal antibody	0.3 mg/kg	Subcutaneous

Effects of XOMA 052 on Insulin Production in Type 1 Diabetes

Summary

Timeline

Drugs

Indications